The drug of interest could either modulate the expression of the immune checkpoint (receptor or ligand), or induce a degradation of the PD-L1 ligand expressed on cancer cells, or contribute to strengthening the blockade of the PD-1/PD-L1 interaction via binding to PD-L1 (Figure 1). This evidence concerns the gene CD274 and cancer.